Tyra Biosciences is developing dabogratinib, a drug targeting FGFR3-related diseases, with a key trial readout expected in September 2026. Success in this trial could validate the drug's effectiveness and safety, enhancing confidence in TYRA's broader SNAP drug-design platform. The company also has other pipeline drugs, SURF303 and BEACH301, planned for 2027, and appears financially supported through these clinical developments. This positions TYRA as a speculative buy for investors interested in biotech innovation with upcoming catalysts.
FLSmidth & Co. A/S continued its share buy-back program initiated on 18 May 2026, repurchasing 61,000 shares between 3 and 7 August 2026 at prices ranging from DKK 487.45 to DKK 511.77 per share. This brings the total shares bought back under the pro...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of early August 2026, the bank has repurchased shares worth approximately DKK 1.57 billion at an average price of D...
Jyske Bank has continued its share repurchase program initiated in February 2026, acquiring shares valued at approximately DKK 1.57 billion by early August 2026. The program, which runs until January 29, 2027, allows the bank to buy back shares up to...
Quadient has been named among the leading providers in The Forrester Wave™: Accounts Payable Invoice Automation Software, Q2 2026, marking its first inclusion in this key industry evaluation. The recognition highlights Quadient's growing presence and...
Australia's financial regulator AUSTRAC has suspended Cryptolink's registration as a virtual asset service provider for three months, effectively halting operations of its 96 Bitcoin ATMs. The suspension follows failures in transaction reporting, inc...
